90 related articles for article (PubMed ID: 17240820)
1. Lung cancer staging in the genomics era.
Nguyen DM; Schrump DS
Thorac Surg Clin; 2006 Nov; 16(4):329-37. PubMed ID: 17240820
[TBL] [Abstract][Full Text] [Related]
2. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation.
Botling J; Edlund K; Lohr M; Hellwig B; Holmberg L; Lambe M; Berglund A; Ekman S; Bergqvist M; Pontén F; König A; Fernandes O; Karlsson M; Helenius G; Karlsson C; Rahnenführer J; Hengstler JG; Micke P
Clin Cancer Res; 2013 Jan; 19(1):194-204. PubMed ID: 23032747
[TBL] [Abstract][Full Text] [Related]
3. Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer.
Yang Y; Pospisil P; Iyer LK; Adelstein SJ; Kassis AI
PLoS One; 2008; 3(11):e3661. PubMed ID: 18987750
[TBL] [Abstract][Full Text] [Related]
4. Molecular biologic staging of lung cancer.
D'Amico TA
Ann Thorac Surg; 2008 Feb; 85(2):S737-42. PubMed ID: 18222207
[TBL] [Abstract][Full Text] [Related]
5. A critical appraisal of prognostic and predictive factors for common lung cancers.
Thunnissen FB; Schuurbiers OC; den Bakker MA
Histopathology; 2006 Jun; 48(7):779-86. PubMed ID: 16722925
[TBL] [Abstract][Full Text] [Related]
6. Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung.
O-charoenrat P; Rusch V; Talbot SG; Sarkaria I; Viale A; Socci N; Ngai I; Rao P; Singh B
Clin Cancer Res; 2004 Sep; 10(17):5792-803. PubMed ID: 15355908
[TBL] [Abstract][Full Text] [Related]
7. Cytosine methylation profiles as a molecular marker in non-small cell lung cancer.
Ehrich M; Field JK; Liloglou T; Xinarianos G; Oeth P; Nelson MR; Cantor CR; van den Boom D
Cancer Res; 2006 Nov; 66(22):10911-8. PubMed ID: 17108128
[TBL] [Abstract][Full Text] [Related]
8. A prognostic test for adenocarcinoma of the lung from gene expression profiling data.
Gordon GJ; Richards WG; Sugarbaker DJ; Jaklitsch MT; Bueno R
Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):905-10. PubMed ID: 14504202
[TBL] [Abstract][Full Text] [Related]
9. Molecular signatures in biopsy specimens of lung cancer.
Borczuk AC; Shah L; Pearson GD; Walter KL; Wang L; Austin JH; Friedman RA; Powell CA
Am J Respir Crit Care Med; 2004 Jul; 170(2):167-74. PubMed ID: 15087295
[TBL] [Abstract][Full Text] [Related]
10. Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer.
Baty F; Facompré M; Kaiser S; Schumacher M; Pless M; Bubendorf L; Savic S; Marrer E; Budach W; Buess M; Kehren J; Tamm M; Brutsche MH
Am J Respir Crit Care Med; 2010 Jan; 181(2):181-8. PubMed ID: 19833826
[TBL] [Abstract][Full Text] [Related]
11. Stratification of the biologic aggressiveness of non-small cell lung cancer using DNA flow cytometry and immunohistochemistry for the retinoblastoma protein.
Otsuka H; Funai S; Tanaka A; Hara S; Shiozaki H
Lung Cancer; 2004 Sep; 45(3):307-16. PubMed ID: 15301871
[TBL] [Abstract][Full Text] [Related]
12. Establishment and comparative characterization of novel squamous cell non-small cell lung cancer cell lines and their corresponding tumor tissue.
Gottschling S; Jauch A; Kuner R; Herpel E; Mueller-Decker K; Schnabel PA; Xu EC; Muley T; Sültmann H; Bender C; Granzow M; Efferth T; Hoffmann H; Dienemann H; Herth FJ; Meister M
Lung Cancer; 2012 Jan; 75(1):45-57. PubMed ID: 21684623
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients.
Son JW; Jeong KJ; Jean WS; Park SY; Jheon S; Cho HM; Park CG; Lee HY; Kang J
Cancer Lett; 2011 Dec; 311(1):29-37. PubMed ID: 21757291
[TBL] [Abstract][Full Text] [Related]
15. Gene expression-based prognostic signatures in lung cancer: ready for clinical use?
Subramanian J; Simon R
J Natl Cancer Inst; 2010 Apr; 102(7):464-74. PubMed ID: 20233996
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts.
Hayes DN; Monti S; Parmigiani G; Gilks CB; Naoki K; Bhattacharjee A; Socinski MA; Perou C; Meyerson M
J Clin Oncol; 2006 Nov; 24(31):5079-90. PubMed ID: 17075127
[TBL] [Abstract][Full Text] [Related]
17. Application of genomic biomarkers to predict increased lung tumor incidence in 2-year rodent cancer bioassays.
Thomas RS; Pluta L; Yang L; Halsey TA
Toxicol Sci; 2007 May; 97(1):55-64. PubMed ID: 17311802
[TBL] [Abstract][Full Text] [Related]
18. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.
Lindgren D; Frigyesi A; Gudjonsson S; Sjödahl G; Hallden C; Chebil G; Veerla S; Ryden T; Månsson W; Liedberg F; Höglund M
Cancer Res; 2010 May; 70(9):3463-72. PubMed ID: 20406976
[TBL] [Abstract][Full Text] [Related]
19. Expression profiling defines a recurrence signature in lung squamous cell carcinoma.
Larsen JE; Pavey SJ; Passmore LH; Bowman R; Clarke BE; Hayward NK; Fong KM
Carcinogenesis; 2007 Mar; 28(3):760-6. PubMed ID: 17082175
[TBL] [Abstract][Full Text] [Related]
20. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis.
Tomida S; Takeuchi T; Shimada Y; Arima C; Matsuo K; Mitsudomi T; Yatabe Y; Takahashi T
J Clin Oncol; 2009 Jun; 27(17):2793-9. PubMed ID: 19414676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
